China Livzon Pharma affiliate's COVID-19 vaccine candidate enters phase III trial

1 minute read

A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

BEIJING, Aug 26 (Reuters) - A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc (Livzon) (000513.SZ) has entered a late-stage trial, Livzon said late on Thursday.

A Phase III trial to evaluate the safety and efficacy of the candidate, named V-01, in people aged 18 and over has started recruiting participants in the Philippines, Livzon said in a filing.

Livzon's affiliate has submitted applications for Phase III clinical trial approval in more than 10 countries, according to the filing.

Reporting by Roxanne Liu and Ryan Woo; Editing by Alex Richardson, Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters